A Common Diabetes Drug May Hold the Key to Stopping HIV From Coming Back

A Common Diabetes Drug May Hold the Key to Stopping HIV From Coming Back For millions of people living with HIV, daily antiretroviral therapy is a lifelong necessity. Stopping treatment typically leads to viral rebound within weeks as the virus reactivates from hidden reservoirs. However, a small subset of individuals naturally maintain viral control for months or even years after discontinuing therapy, a phenomenon known as post-treatment control. Recent research suggests that metformin, a widely prescribed medication for type 2 diabetes, may help replicate this natural control by targeting mechanisms that preserve HIV in a dormant state. Scientists at the Gladstone Institutes investigated why some people suppress HIV without medication after stopping antiretroviral therapy. Their study, published in the journal Immunity, identified two specific genes within infected cells that function as “security locks” to maintain viral latency. One of these genes can be activated by metformin, promoting a deeper dormant state that delays or prevents viral rebound. According to Nadia Roan, PhD, senior investigator at Gladstone and senior author on the study, “Our data suggest metformin might be able to delay, or possibly even prevent HIV rebound in some individuals, which is exciting because it’s a very safe and affordable drug.” These findings align with earlier research demonstrating metformin’s dual effects on HIV. A 2024 study in Aging and Disease reported that metformin increases HIV transcription through enhanced CREB phosphorylation and recruitment to the HIV LTR promoter, suggesting a proviral effect under certain conditions. Conversely, research from the University of Montreal’s CRCHUM, published in iScience in 2024, showed that metformin reduces chronic inflammation and inhibits mTOR activity, which slows HIV replication in CD4 T lymphocytes. The same study noted that metformin overexpresses the BST2 protein, which traps virions on the surface of infected cells, limiting their release and spread. Preclinical work from the UNC School of Medicine in 2021 indicated that metformin reduces the metabolic activity of infected T cells, potentially limiting the energy available for viral replication. Together, these studies suggest that metformin may influence HIV persistence through multiple mechanisms—modulating immune activation, altering cellular metabolism, and enhancing restrictions on viral release—though its net effect appears to depend on context, including cell type, drug concentration, and the stage of infection. Even as metformin is not a cure for HIV, its ability to promote viral dormancy and reduce reservoir activity positions it as a promising candidate for strategies aimed at achieving long-term remission without daily antiretrovirals. Researchers emphasize the need for clinical trials to determine whether metformin can safely and effectively prolong post-treatment control in people living with HIV. Given its decades-long safety profile, low cost, and global availability, metformin represents a practical avenue for advancing functional cure research, particularly in resource-limited settings. As scientists continue to unravel the complex interactions between metabolism, immunity, and viral latency, repurposing existing drugs like metformin offers a pragmatic path toward sustainable HIV management. Future studies will clarify which populations are most likely to benefit and how metformin might be combined with other interventions to maximize durable viral control.